Source comparison
BPC-157 Research Hormone Panel Tracking: Complete Comparison
IGF-1 7–14 days pre-admin +5–15% (injury present) +10–20% (injury present) Return to baseline No change if no active tissue damage. Not a GH secretagogue IGFBP-3 +3–10% +5–12% Binding protein. Tracks with IGF-1, confirms growth axis involvement TSH No change S
This comparison does not assign a generated winner or score.
- IGF-1
- 7–14 days pre-admin
- +5–15% (injury present)
- +10–20% (injury present)
- Return to baseline
- No change if no active tissue damage. Not a GH secretagogue
- IGFBP-3
- +3–10%
- +5–12%
- Binding protein. Tracks with IGF-1, confirms growth axis involvement
- TSH
- No change
- Stable or slight decrease
- Stable
- Elevation = thyroid axis strain from repair demands
- Free T3
- +3–8%
- +5–10%
- Peripheral conversion increase supports metabolic repair demands
- CRP
- −20–40%
- −30–50%
- Persistent elevation = inadequate dose or confounding inflammation
- IL-6
- −25–45%
- −35–55%
- More sensitive than CRP for acute anti-inflammatory effects
- Cortisol (AM)
- −10–20% (if elevated baseline)
- −15–25% (if elevated baseline)
- Flattening below range = HPA suppression. Reduce dose
- VEGF
- +15–30%
- Peak ~+30–40%
- Confirms angiogenic activity. No rise questions peptide potency